Skip to content

Long-term Outcome of Bronchopulmonary Dysplasia * Focus on Cardiovascular Health

Long-term Outcome of Bronchopulmonary Dysplasia * Focus on Cardiovascular Health - MRI-exercise study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47123
Enrollment
76
Registered
2016-08-19
Start date
2018-12-19
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular health chronic lung disease in premature babies

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Healthy control group (n30 %.

Exclusion criteria

Exclusion criteria: - Known acquired or congenital hemodynamically significant heart disease (except heart disease as a consequence of pulmonary hypertension) - Pulmonary disorders other than BPD - Kidney disorders - Neurodevelopmental disabilities that would prevent cooperation with CPET and/or CMR imaging. - Absence of written informed consent

Design outcomes

Primary

MeasureTime frame
Part A: MR cardiopulmonary exercise protocol validation: The main study parameter is the increase in oxygen consumption of subjects in relation to workload increase during a exercise test on a MR-ergometer and on a conventional ergometer. Part B: CMR exercise study: The main study parameter is stroke volume of the right ventricle.

Secondary

MeasureTime frame
Part A: MR cardiopulmonary exercise protocol validation: Other parameters are maximal heart frequency, CO2 production, respiratory coefficient. Part B: CMR exercise study: Other study parameters are exercise capacity (peak oxygen uptake, VO2max) and several parameters for assessment of lung function (forced expired volume in 1 second, FEV, total lung capacity, TLC, fractional residual capacity, FRC, diffusion capacity for carbon monoxide, DLCO), and assessment of cardiac function and structure (e.g. heart ventricular mass/volume ratio, tricuspid regurgitation velocity, heart ventricular longitudinal strain and ejection fraction).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)